Biogen

A humanized amyloid-beta (Aβ) monoclonal antibody (mAb) that binds to amyloid and can potentially reduce amyloid presence in the brain and slow the progress of Alzheimer’s Disease. Leqembi was the first anti-amyloid beta treatment with FDA traditional approval in the U.S. Eisai leads the global development and regulatory submissions of Leqembi, with both Eisai and Biogen collaborating on commercialization and co-promotion, while Eisai holds final decision-making authority.